doxazosin has been researched along with Cardiomegaly in 9 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 9.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 9.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 7.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 5.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 5.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 3.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "After hypertension was controlled with doxazosin (a long-acting alpha 1 adrenergic blocker), her cardiac function gradually improved." | 1.29 | Severe hypertension and cardiac failure associated with neuroblastoma: a case report. ( Akiba, K; Hayasaka, K; Katsuura, M; Obata, K; Otaki, S; Sato, S; Sendo, D; Tanabe, S; Wakabayashi, T; Yamagiwa, I; Yokoyama, S, 1996) |
| " Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)." | 1.28 | Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boesen, EI | 1 |
| Lewis, TV | 1 |
| Kett, MM | 1 |
| Anderson, WP | 1 |
| Asai, T | 1 |
| Kushiro, T | 1 |
| Fujita, H | 1 |
| Kanmatsuse, K | 1 |
| Perlini, S | 1 |
| Palladini, G | 1 |
| Ferrero, I | 1 |
| Tozzi, R | 1 |
| Fallarini, S | 1 |
| Facoetti, A | 1 |
| Nano, R | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Fogari, R | 1 |
| Ferrari, AU | 1 |
| Sendo, D | 1 |
| Katsuura, M | 1 |
| Akiba, K | 1 |
| Yokoyama, S | 1 |
| Tanabe, S | 1 |
| Wakabayashi, T | 1 |
| Sato, S | 1 |
| Otaki, S | 1 |
| Obata, K | 1 |
| Yamagiwa, I | 1 |
| Hayasaka, K | 1 |
| Agabiti-Rosei, E | 1 |
| Muiesan, ML | 1 |
| Rizzoni, D | 1 |
| Zulli, R | 1 |
| Calebich, S | 1 |
| Beschi, M | 1 |
| Castellano, M | 1 |
| Muiesan, G | 1 |
| Leren, P | 1 |
| Taylor, SH | 1 |
| Corral, JL | 1 |
| López, NC | 1 |
| Pecorelli, A | 1 |
| Rincón, LA | 1 |
| Terán, VD | 1 |
| Monsalve, P | 1 |
| Vera, O | 1 |
| Pérez Acuña, F | 1 |
| Medina, O | 1 |
| Ostojich, K | 1 |
| López, B | 1 |
| Torres, N | 1 |
| Lugo de Franco, V | 1 |
| Fonseca, R | 1 |
2 reviews available for doxazosin and Cardiomegaly
| Article | Year |
|---|---|
The cardiovascular effects of alpha-receptor blocking agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cardiovascular System; | 1992 |
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
2 trials available for doxazosin and Cardiomegaly
| Article | Year |
|---|---|
Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Doxazosin; Echocardiography; Female; Humans; Hypertens | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F | 1991 |
5 other studies available for doxazosin and Cardiomegaly
| Article | Year |
|---|---|
Effects of preweaning doxazosin treatment on adult pressure in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Animals, Suckling; Blood Pressure; Cardiomegaly; Doxazosin; F | 2003 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Rec | 2005 |
Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiomegaly; Co | 2005 |
Severe hypertension and cardiac failure associated with neuroblastoma: a case report.
Topics: Adrenergic alpha-Antagonists; Cardiomegaly; Catecholamines; Child, Preschool; Doxazosin; Female; Gan | 1996 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg | 1992 |